The company recently urged shareholders to approve the deal, saying the cash consideration they'd receive would represent a premium over recent stock prices.
The single-cell analysis firm told shareholders that while the final offer from Takara is not set in stone, they're unlikely to be offered better terms.
Last month, the companies announced that Takara Bio USA — formerly Clontech Laboratories and now a subsidiary of Japan's Takara Bio — would acquire WaferGen.